Expert review of molecular diagnostics · 2026
Dual germline BRCA and mismatch-repair mutations: a narrative review.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Rui, Ge Chuang, Yuan Fang, Fu Kaiwen, Long Xingtao, Wu Ke, Wang Lifeng
Аннотация
INTRODUCTION: Multilocus inherited neoplasia alleles syndrome (MINAS) can pair a germline pathogenic BRCA1/2 variant with a pathogenic mismatch-repair (MMR) variant, but current guidelines manage the two inherited pathways separately.
AREAS COVERED: We searched PubMed, Embase, the American Society of Clinical Oncology Library, European Society for Medical Oncology OncologyPro, and Society of Gynecologic Oncology library from 2011 to 17 May 2026. It distinguishes a dual germline carrier from single-track, dual-defective, and biomarker-discordant tumors. For mismatch-repair immunohistochemistry (IHC)-deficient but microsatellite-stable results, particularly with isolated MSH6 loss, we propose technical review followed by a validated orthogonal assay when needed. The evidence for poly(ADP-ribose) polymerase inhibitor (PARPi) plus immune checkpoint inhibitor (ICI) therapy is assessed through the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) hypothesis and TOPACIO, MEDIOLA, and DUO-E.
EXPERT OPINION: Management should combine gene-specific surveillance with tumor-level biomarkers and shared decision-making. Treatment should not be inferred from dual germline status alone, and no phase III trial has predefined dual carriers as a treatment stratum.
AREAS COVERED: We searched PubMed, Embase, the American Society of Clinical Oncology Library, European Society for Medical Oncology OncologyPro, and Society of Gynecologic Oncology library from 2011 to 17 May 2026. It distinguishes a dual germline carrier from single-track, dual-defective, and biomarker-discordant tumors. For mismatch-repair immunohistochemistry (IHC)-deficient but microsatellite-stable results, particularly with isolated MSH6 loss, we propose technical review followed by a validated orthogonal assay when needed. The evidence for poly(ADP-ribose) polymerase inhibitor (PARPi) plus immune checkpoint inhibitor (ICI) therapy is assessed through the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) hypothesis and TOPACIO, MEDIOLA, and DUO-E.
EXPERT OPINION: Management should combine gene-specific surveillance with tumor-level biomarkers and shared decision-making. Treatment should not be inferred from dual germline status alone, and no phase III trial has predefined dual carriers as a treatment stratum.